Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness or hyperemia: mild irritation of conjunctival vessels. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of eye color. - Eye irritation or foreign body sensation. - Blurred vision: transient after instillation. - Periorbital skin darkening.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis, iritis). - Allergic contact dermatitis of the eyelid. - Sudden loss of vision or visual field defects. - Corneal edema or endothelial decompensation. - Persistent ocular pain or photophobia. - Systemic hypersensitivity reactions.

Before using Latanoprost, patients and clinicians should consider the following safety points. Monitor intra‑ocular pressure: ensure target pressure is achieved and maintained. Avoid contact lens wear for at least 15 minutes after instillation to prevent lens contamination. Assess for active ocular infection or inflammation: defer use until resolved. Use with caution in patients with a history of cystoid macular edema. Discontinue if severe ocular inflammation or allergic reaction occurs. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may increase risk of ocular hyperemia and pigmentary changes. - Use with ocular inflammation‑inducing agents (e.g., certain steroids): can exacerbate inflammation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may alter ocular surface tolerance. - Systemic beta‑blockers: monitor blood pressure and heart rate when combined with other IOP‑lowering drugs. - CYP450 inhibitors (e.g., ketoconazole): may affect systemic clearance of latanoprost metabolites. - Anticholinergic eye drops: monitor for additive pupil dilation effects.